## NTriMas

Third Quarter 2020 Earnings Presentation


## Forward-Looking Statement

Any "forward-looking" statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, contained herein, including those relating to TriMas' business, financial condition or future results, involve risks and uncertainties with respect to, including, but not limited to: severity and duration of the ongoing coronavirus ("COVID-19") pandemic on our operations, customers and suppliers, as well as related actions taken by governmental authorities and other third parties in response, each of which is uncertain, rapidly changing and difficult to predict; general economic and currency conditions; material and energy costs; risks and uncertainties associated with intangible assets, including goodwill or other intangible asset impairment charges; competitive factors; future trends; the Company's ability to realize its business strategies; the Company's ability to identify attractive acquisition candidates, successfully integrate acquired operations or realize the intended benefits of such acquisitions; information technology and other cyber-related risks; the performance of subcontractors and suppliers; supply constraints; market demand; intellectual property factors; litigation; government and regulatory actions, including, but not limited to, the impact of tariffs, quotas and surcharges; the Company's leverage; liabilities imposed by debt instruments; labor disputes; changes to fiscal and tax policies; contingent liabilities relating to acquisition activities; the disruption of operations from catastrophic or extraordinary events, including natural disasters and public health crises; the potential impact of Brexit; tax considerations relating to the Cequent spin-off; the Company's future prospects; and other risks that are detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in the Third Quarter 2020 report on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements, except as required by law.

## Non-GAAP Financial Measures

In this presentation, certain non-GAAP financial measures may be used. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measure may be found in the Appendix at the end of this presentation or in the earnings releases available on the Company's website. Additional information is available at www.trimascorp.com under the "Investors" section.

Please see the Appendix for details regarding certain costs, expenses and other amounts or charges, collectively described as "Special Items," that are included in the determination of net income, earnings per share and/or cash flows from operating activities under GAAP, but that management believes should be separately considered when evaluating the quality of the Company's core operating results, given they may not reflect the ongoing activities of the business. Management believes that presenting these non-GAAP financial measures, adjusting for Special Items, provides useful information to investors by helping them identify underlying trends in the Company's businesses and facilitating comparisons of performance with prior and future periods. These non-GAAP financial measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP financial measures.

## NTriMas

- Strong Brand Names
- Diverse End Markets
- Innovative Product Solutions
- Exceptional Cash Conversion


As of 9/30/20, TriMas reported LTM Sales of \$752.7 million, Adjusted EBITDA ${ }^{(1)}$ of $\$ 154.1$ million, or 20.5\% of sales, and Segment Adjusted EBITDA ${ }^{(1)}$ of $\$ 173.9$ million, or $\mathbf{2 3 . 1 \%}$ of sales.

## TriMas Growth Strategy

TriMas unleashes value across our portfolio of businesses through...


Disciplined approach to capital allocation and maintaining a strong balance sheet.

- Designer and manufacturer of engineered caps and closures for food \& beverage and industrial applications
- Aseptic closures for energetic, juice and dairy drinks, as well as industrial caps, closures and flex spouts with tamper evident and child-proof features
- Global reach with a strong focus on Euro-CPG customers
- Highly-automated manufacturing plant located in Borgo San Giovanni, Italy
- Important food packaging qualifications and safety certifications
- TriMas acquisition rationale:
$\checkmark$ Offers proprietary product designs and aseptic manufacturing capabilities
$\checkmark$ Expands food \& beverage offering in Europe
$\checkmark$ Enhances high volume manufacturing capabilities and adds industrial capacity in Europe
$\checkmark$ Increases potential when combined with recent acquisitions and TriMas' global footprint
- Expected to generate $€ 32$ million in revenue in FY 2020



## Q3 2020 Results

| Adjusted for Special Items | Q3 2020 | Q3 2019 | YOY Growth \% |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | \$199.5 | \$188.4 |  | Organic | quisitions | Fx | Total |
|  |  |  | Consolidated TriMas | 0.4\% | 5.1\% | 0.4\% | 5.9\% |
| Operating Profit | \$29.6 | \$24.6 | Packaging | 22.8\% | 4.7\% | 0.6\% | 28.1\% |
| Operating Profit Margin | 14.8\% | 13.1\% | Aerospace | -31.8\% | 9.2\% |  | -22.6\% |
| Net Income | \$18.6 | \$16.1 | Specialty Products | -22.1\% |  |  | -22.1\% |
| Diluted Earnings Per Share | \$0.43 | \$0.36 |  |  |  |  |  |
| Adjusted EBITDA ${ }^{(1)}$ | \$41.6 | \$37.2 |  |  |  |  |  |
| Adjusted EBITDA Margin | 20.8\% | 19.8\% |  |  |  |  |  |
| Segment Adjusted EBITDA ${ }^{(1)}$ | \$46.7 | \$42.8 |  |  |  |  |  |
| Segment Adjusted EBITDA Margin | 23.4\% | 22.7\% |  |  |  |  |  |

- Record sales in Packaging and the impact of recent acquisitions offset sales declines in Aerospace and Specialty Products related to weaker demand resulting from the COVID-19 pandemic
- Operating profit increased $20.3 \%$ as a result of the impact of higher sales and a more favorable product mix
- Achieved Q3 EPS of \$0.43 per share, a 19.4\% increase as compared with Q3 2019
- Adjusted EBITDA ${ }^{(1)}$ increased by nearly $\$ 4.4$ million, with the related margin increasing 100 bps


## Strong quarter despite impacts related to the global pandemic.

[^0]| Adjusted for Special Items | Q3 2020 YTD | Q3 2019 YTD | YOY Growth \% |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | \$581.8 | \$552.6 |  | Organic | Acquisitions | Fx | Total |
| Net Sales | \$581.8 | \$552.6 | Consolidated TriMas | -0.2\% | 6.0\% | -0.5\% | 5.3\% |
| Operating Profit | \$79.1 | \$75.0 | Packaging | 16.4\% | 6.5\% | -0.9\% | 22.0\% |
| Operating Profit Margin | 13.6\% | 13.6\% | Aerospace | -19.6\% | 9.3\% |  | -10.3\% |
| Net Income | \$52.4 | \$52.3 | Specialty Products | -19.8\% |  |  | -19.8\% |
| Diluted Earnings Per Share | \$1.19 | \$1.14 |  |  |  |  |  |
| Adjusted EBITDA ${ }^{(1)}$ | \$120.1 | \$112.6 |  |  |  |  |  |
| Adjusted EBITDA Margin | 20.6\% | 20.4\% |  |  |  |  |  |
| Segment Adjusted EBITDA ${ }^{(1)}$ | \$133.9 | \$130.0 |  |  |  |  |  |
| Segment Adjusted EBITDA Margin | 23.0\% | 23.5\% |  |  |  |  |  |

- YTD net sales increased 5.3\% due to organic sales growth of dispenser and closure products used in applications that help fight the spread of germs, as well as acquisitions
- Operating profit increased $5.4 \%$, as the impact of higher sales was partially offset by pandemicrelated production inefficiencies, and higher depreciation, amortization and non-cash stock compensation expense
- Achieved YTD EPS of \$1.19 per share, a 4.4\% increase as compared to Q3 2019 YTD
- Adjusted EBITDA ${ }^{(1)}$ increased by approximately $\$ 7.5$ million


## Strong Packaging performance, plus acquisitions, offset unfavorable impacts of the global pandemic.

[^1]
## Free Cash Flow \& Net Debt

## Continued Strong Financial Position

- TriMas capital structure and commitment to generating free cash flow drive our deleveraging model
- Generated strong free cash flow from continuing operations in Q3
- Q3 2020 Free Cash Flow ${ }^{(1)}$ of $\$ 41.6$ million, as compared to $\$ 19.3$ million in Q3 2019
- As of September 30, 2020, unrestricted cash \& availability of $\$ 389.2$ million and Bank Leverage ${ }^{(2)}$ of 1.4 x
- Repurchased more than 1.5 million shares, or $\sim 3.4 \%$ of shares outstanding, for $\$ 38.2$ million, year-todate through October 16, 2020
- Repurchased more than 188,000 shares for $\$ 4.5$ million in Q3

| Key Credit Statistics | Q3 2020 | Q3 2019 |
| :--- | :---: | :---: |
| Total Debt | $\$ 295.6$ | $\$ 294.4$ |
| Less: Cash | $\$ 99.7$ | $\$ 57.9$ |
| Net Debt | $\$ 195.8$ | $\$ 236.5$ |
| LTM Adjusted EBITDA $^{(3)}$ | $\$ 154.1$ | $\$ 148.6$ |
| Net Leverage $^{(4)}$ | 1.3 x | 1.6 x |
| Free Cash Flow $^{(1)}$ | $\$ 41.6$ | $\$ 19.3$ |

## Continued strong balance sheet and cash flow during the quarter.

[^2](1) Free Cash Flow is defined as Net Cash Provided by/(Used for) Operating Activities from continuing operations, excluding the cash impact of Special Items, less capital expenditures.
(2) As defined in the Company's Credit Agreement.
(3) Adjusted EBITDA is defined as income (loss) from continuing operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock compensation, all as adjusted for the impact of Special Items.
(4) Net Leverage is defined as Net Debt/LTM Adjusted EBITDA.

## TriMas

Segment Results

## TriMas Packaging Segment

| Adjusted for Special Items | Q3 2020 | Q3 2019 |
| :--- | :--- | :--- |
| Net Sales | $\$ 135.1$ | $\$ 105.5$ |
| Operating Profit | $\$ 28.0$ | $\$ 20.1$ |
| Operating Margin | $20.7 \%$ | $19.1 \%$ |
| Adjusted EBITDA |  |  |
| Adjusted EBITDA Margin | $\$ 34.2$ | $\$ 26.8$ |

# rieke <br> taplast $\cong$ Rapak 



## Quarterly Takeaways

- Record sales quarter driven by demand increases for beauty \& personal care, home care, and food \& beverage applications, and the impact of acquisitions
- Operating profit and margins increased as a result of higher sales levels, offsetting production scheduling inefficiencies related to the global pandemic's impact on operations and higher SG\&A
- Signed agreement to acquire Affaba \& Ferrari; continuing to build out TriMas' Packaging platform

| Adjusted for Special Items | Q3 2020 | Q3 2019 |
| :--- | :---: | :---: |
| Net Sales | $\$ 39.1$ | $\$ 50.6$ |
| Operating Profit | $\$ 3.7$ | $\$ 7.8$ |
| Operating Margin | $9.5 \%$ | $15.4 \%$ |
| Adjusted EBITDA |  |  |
| Adjusted EBITDA Margin | $\$ 8.2$ | $\$ 11.5$ |

## TriMas

AEROSPACE ${ }^{n *}$


MACゅFASTENERS

MARTINIC
ENGINEERING ${ }^{\text {w" }}$

## Quarterly Takeaways

- Sales declined due to the impact of significantly reduced aircraft production as a result of the effects of the global pandemic, partially offset by sales related to the RSA acquisition
- Operating profit and related margins impacted by reduced sales, lower absorption of fixed costs and pandemic-related production inefficiencies, despite realignment actions
- Recorded $\$ 134.6$ million of pre-tax, non-cash goodwill and intangible asset impairment charges during Q3 as a result of a significant decline in results, as well as uncertainty around the duration and magnitude of the pandemic's impact on future air travel and new aircraft demand

[^3]
## TriMas Specialty Products Segment

| Adjusted for Special Items | Q3 2020 | Q3 2019 |
| :--- | :--- | :--- |
| Net Sales | $\$ 25.2$ | $\$ 32.4$ |
| Operating Profit | $\$ 3.4$ | $\$ 3.6$ |
| Operating Margin | $13.4 \%$ | $11.2 \%$ |
| Adjusted EBITDA |  |  |
| Adjusted EBITDA Margin | $\$ 4.3$ | $\$ 4.5$ |




## Quarterly Takeaways

- Continued lower demand for Norris steel cylinder products in the industrial end market and Arrow Engine products as a result of oil \& gas end market weakness, both resulting from the effects of the pandemic
- Operating profit impacted by lower sales volumes
- Previous realignment actions and streamlining of product focus enhanced margins despite lower demand


## TriMas

Summary

| TriMas FY 2020 Outlook |  |
| :---: | :---: |
| Sales and \% Change vs. FY 2019 |  |
| Consolidated TriMas | $\$ 752 \mathrm{M}-\$ 767 \mathrm{M}$ <br> $4 \%$ to $6 \%$ |
| TriMas Packaging Group | $\$ 475 \mathrm{M}-$ \$ 483 M <br> $21 \%$ to $23 \%$ |
| TriMas Aerospace Group | $\$ 165 \mathrm{M}-\$ 171 \mathrm{M}$ <br> $-15 \%$ to $-12 \%$ <br> $\$ 110 \mathrm{M}-\$ 114 \mathrm{M}$ <br> $-20 \%$ to $-17 \%$ |
| Specialty Products Group |  |

## Initial 2021 Thoughts

## Consolidated TriMas

- Anticipate organic sales growth year-over-year, plus acquisitions
- Strong free cash flow generation greater than $100 \%$ of net income


## TriMas Packaging Group

- Year-over-year sales increase driven by acquisitions
- Pandemic-related pipeline expected to stabilize

TriMas Aerospace Group

- Year-over-year sales increase driven by ramp of new business awards and full year benefit of acquisition
- Overall market demand challenges consistent with second half 2020 run-rates


## Specialty Products Group

- Relatively flat sales year-over-year
- Potential cylinder demand recovery when the pandemic subsides

Expect to continue positive momentum, while managing through the effects of the pandemic.

Note: All of the figures on this slide are adjusted for any current and future Special Items. FY 2020 Outlook excludes any impact related to the recently announced Affaba \& Ferrari acquisition.
(1) Free Cash Flow is defined as Net Cash Provided by/(Used for) Operating Activities from continuing operations, excluding the cash impact of Special Items, less capital expenditures.

## TriMas Value Drivers

New compelling value drivers have emerged as a result of the pandemic, while prior value drivers remain...

1. Accelerate organic growth in dispensing and closure products given new global secular trends in personal hygiene and cleaning applications
2. Position challenged businesses for early wins in an economic recovery with increased operating leverage as a result of 2020 realignment actions

3. Enhance growth through $M \& A$, focused in Packaging and Aerospace platforms
4. Continue to return capital to shareholders through share buybacks
5. Maintain strong balance sheet, liquidity and cash generation to execute TriMas' Growth Strategy

Disciplined approach to capital allocation and prior actions position TriMas for long-term value creation.

## TriMas

Q \& A

## TriMas

Appendix

## Condensed Consolidated Balance Sheet

|  | September 30, 2020 |  | $\begin{gathered} \text { December 31, } \\ 2019 \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
| (unaudited) |  |  |  |  |
| Assets |  |  |  |  |
| Current assets: |  |  |  |  |
| Cash and cash equivalents | \$ | 99,740 | \$ | 172,470 |
| Receivables, net |  | 118,750 |  | 108,860 |
| Inventories |  | 142,600 |  | 132,660 |
| Prepaid expenses and other current assets |  | 13,640 |  | 20,050 |
| Total current assets |  | 374,730 |  | 434,040 |
| Property and equipment, net |  | 215,630 |  | 214,330 |
| Operating lease right-of-use assets |  | 36,050 |  | 27,850 |
| Goodwill |  | 251,870 |  | 334,640 |
| Other intangibles, net |  | 175,590 |  | 161,390 |
| Deferred income taxes |  | 5,720 |  | 500 |
| Other assets |  | 15,930 |  | 19,950 |
| Total assets | \$ | 1,075,520 | \$ | 1,192,700 |
|  |  |  |  |  |
| Liabilities and Shareholders' Equity |  |  |  |  |
| Current liabilities: |  |  |  |  |
| Accounts payable | \$ | 59,530 | \$ | 72,670 |
| Accrued liabilities |  | 56,410 |  | 42,020 |
| Operating lease liabilities, current portion |  | 6,940 |  | 5,100 |
| Total current liabilities |  | 122,880 |  | 119,790 |
| Long-term debt, net |  | 295,550 |  | 294,690 |
| Operating lease liabilities |  | 29,650 |  | 23,100 |
| Deferred income taxes |  | 12,220 |  | 16,830 |
| Other long-term liabilities |  | 57,250 |  | 40,810 |
| Total liabilities |  | 517,550 |  | 495,220 |
| Total shareholders' equity |  | 557,970 |  | 697,480 |
| Total liabilities and shareholders' equity | \$ | 1,075,520 | \$ | 1,192,700 |

## Consolidated Statement of Operations

|  | Three months ended September 30, |  |  |  | Nine months ended September 30, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 2020 |  | 2019 |  | 2020 |  | 2019 |
|  | (unaudited) |  |  |  |  |  |  |  |
| Net sales | \$ | 199,460 | \$ | 188,410 | \$ | 581,800 | \$ | 552,610 |
| Cost of sales |  | $(147,530)$ |  | $(139,420)$ |  | $(446,270)$ |  | $(403,040)$ |
| Gross profit |  | 51,930 |  | 48,990 |  | 135,530 |  | 149,570 |
| Selling, general and administrative expenses |  | $(25,650)$ |  | $(25,420)$ |  | $(107,570)$ |  | $(79,140)$ |
| Impairment of goodwill and indefinite-lived intangible assets |  | $(134,600)$ |  | - |  | $(134,600)$ |  | - |
| Operating profit (loss) |  | $(108,320)$ |  | 23,570 |  | $(106,640)$ |  | 70,430 |
| Other expense, net: |  |  |  |  |  |  |  |  |
| Interest expense |  | $(3,450)$ |  | $(3,520)$ |  | $(11,260)$ |  | $(10,450)$ |
| Other income (expense), net |  | $(1,200)$ |  | 600 |  | (150) |  | 1,250 |
| Other expense, net |  | $(4,650)$ |  | $(2,920)$ |  | $(11,410)$ |  | $(9,200)$ |
|  |  |  |  |  |  |  |  |  |
| Income (loss) before income tax expense |  | $(112,970)$ |  | 20,650 |  | $(118,050)$ |  | 61,230 |
| Income tax benefit (expense) |  | 12,100 |  | $(5,410)$ |  | 14,600 |  | $(12,720)$ |
| Income (loss) from continuing operations |  | $(100,870)$ |  | 15,240 |  | $(103,450)$ |  | 48,510 |
| Income from discontinued operations, net of tax |  | - |  | 3,870 |  | - |  | 11,710 |
| Net income (loss) | \$ | $(100,870)$ | \$ | 19,110 | \$ | $(103,450)$ | \$ | 60,220 |
|  |  |  |  |  |  |  |  |  |
| Earnings per share - basic: |  |  |  |  |  |  |  |  |
| Continuing operations | \$ | (2.32) | \$ | 0.34 | \$ | (2.37) | \$ | 1.07 |
| Discontinued operations |  | - |  | 0.08 |  | - |  | 0.26 |
| Net income (loss) per share |  | (2.32) | \$ | 0.42 | \$ | (2.37) | \$ | 1.33 |
| Weighted average common shares - basic |  | 43,457,704 |  | 45,175,244 |  | 43,707,331 |  | 45,448,711 |
|  |  |  |  |  |  |  |  |  |
| Earnings per share - diluted: |  |  |  |  |  |  |  |  |
| Continuing operations |  | (2.32) | \$ | 0.34 | \$ | (2.37) | \$ | 1.06 |
| Discontinued operations |  | - |  | 0.08 |  | - |  | 0.26 |
| Net income (loss) per share |  | (2.32) | \$ | 0.42 | \$ | (2.37) | \$ | 1.32 |
| Weighted average common shares - diluted |  | 43,457,704 |  | 45,415,767 |  | 43,707,331 |  | 45,745,421 |

## Consolidated Statement of Cash Flows

|  | Nine months ended September 30, |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  | 2019 |  |
| Cash Flows from Operating Activities: |  |  |  |  |
| Net income (loss) | \$ | $(103,450)$ | \$ | 60,220 |
| Income from discontinued operations |  |  |  | 11,710 |
| Income (loss) from continuing operations |  | $(103,450)$ |  | 48,510 |
| Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities, net of acquisition impact: |  |  |  |  |
| Impairment of goodwill and indefinite-lived intangible assets |  | 134,600 |  | - |
| Loss on dispositions of assets |  | 1,080 |  | 60 |
| Depreciation |  | 21,700 |  | 18,330 |
| Amortization of intangible assets |  | 15,460 |  | 14,030 |
| Amortization of debt issue costs |  | 860 |  | 850 |
| Deferred income taxes |  | $(17,790)$ |  | 5,530 |
| Non-cash compensation expense |  | 5,610 |  | 4,130 |
| Non-cash change in legacy liability estimate |  | 23,400 |  | - |
| Increase in receivables |  | $(6,210)$ |  | $(8,380)$ |
| (Increase) decrease in inventories |  | 4,510 |  | (560) |
| Decrease in prepaid expenses and other assets |  | 5,500 |  | 4,780 |
| Decrease in accounts payable and accrued liabilities |  | $(7,410)$ |  | $(26,760)$ |
| Other operating activities |  | 1,250 |  | 90 |
| Net cash provided by operating activities of continuing operations |  | 79,110 |  | 60,610 |
| Net cash provided by operating activities of discontinued operations |  | - |  | 3,490 |
| Net cash provided by operating activities, net of acquisition impact |  | 79,110 |  | 64,100 |
|  |  |  |  |  |
| Cash Flows from Investing Activities: |  |  |  |  |
| Capital expenditures |  | $(17,670)$ |  | $(22,000)$ |
| Acquisition of businesses, net of cash acquired |  | $(95,160)$ |  | $(67,090)$ |
| Net proceeds from disposition of business, property and equipment |  | 1,930 |  | 10 |
| Net cash used for investing activities of continuing operations |  | $(110,900)$ |  | $(89,080)$ |
| Net cash used for investing activities of discontinued operations |  | - |  | $(1,350)$ |
| Net cash used for investing activities |  | $(110,900)$ |  | $(90,430)$ |
|  |  |  |  |  |
| Cash Flows from Financing Activities: |  |  |  |  |
| Proceeds from borrowings on revolving credit facilities |  | 300,950 |  | 145,540 |
| Repayments of borrowings on revolving credit facilities |  | $(303,240)$ |  | $(145,090)$ |
| Shares surrendered upon exercise and vesting of equity awards to cover taxes |  | $(2,600)$ |  | $(3,240)$ |
| Payments to purchase common stock |  | $(36,050)$ |  | $(21,090)$ |
| Net cash used for financing activities of continuing operations |  | $(40,940)$ |  | $(23,880)$ |
| Net cash provided by financing activities of discontinued operations |  | - |  | - |
| Net cash used for financing activities |  | $(40,940)$ |  | $(23,880)$ |
|  |  |  |  |  |
| Cash and Cash Equivalents: |  |  |  |  |
| Decrease for the period |  | $(72,730)$ |  | $(50,210)$ |
| At beginning of period |  | 172,470 |  | 108,150 |
| At end of period | \$ | 99,740 | \$ | 57,940 |
|  |  |  |  |  |
| Supplemental disclosure of cash flow information: |  |  |  |  |
| Cash paid for interest | \$ | 7,490 | \$ | 6,570 |
| Cash paid for taxes | \$ | 6,660 | \$ | 15,690 |

## Company and Segment Financial Information

|  | Three months ended September 30, |  |  |  | Nine months ended September 30, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  | 2019 |  | 2020 |  | 2019 |  |
| Packaging |  |  |  |  |  |  |  |  |
| Net sales | \$ | 135,120 | \$ | 105,480 | \$ | 364,000 | \$ | 298,310 |
| Operating profit | \$ | 28,020 | \$ | 19,740 | \$ | 70,340 | \$ | 60,020 |
| Special Items to consider in evaluating operating profit: |  |  |  |  |  |  |  |  |
| Purchase accounting costs |  | - |  | - |  | 750 |  | 1,280 |
| Business restructuring and severance costs |  | - |  | 360 |  | 2,730 |  | 360 |
| Adjusted operating profit | \$ | 28,020 | \$ | 20,100 | \$ | 73,820 | \$ | 61,660 |
|  |  |  |  |  |  |  |  |  |
| Aerospace |  |  |  |  |  |  |  |  |
| Net sales | \$ | 39,130 | \$ | 50,560 | \$ | 130,660 | \$ | 145,650 |
| Operating profit (loss) | \$ | $(133,500)$ | \$ | 7,810 | \$ | $(132,630)$ | \$ | 21,270 |
| Special Items to consider in evaluating operating profit: |  |  |  |  |  |  |  |  |
| Impairment of goodwill and indefinite-lived intangible assets |  | 134,600 |  | - |  | 134,600 |  | - |
| Pre-acquisition contingent liability |  | 2,000 |  | - |  | 2,000 |  | - |
| Purchase accounting costs |  | - |  | - |  | 2,030 |  | - |
| Business restructuring and severance costs |  | 600 |  | - |  | 8,110 |  | 440 |
| Adjusted operating profit | \$ | 3,700 | \$ | 7,810 | \$ | 14,110 | \$ | 21,710 |
|  |  |  |  |  |  |  |  |  |
| Specialty Products |  |  |  |  |  |  |  |  |
| Net sales | \$ | 25,210 | \$ | 32,370 | \$ | 87,140 | \$ | 108,650 |
| Operating profit | \$ | 3,380 | \$ | 3,620 | \$ | 870 | \$ | 13,730 |
| Special Items to consider in evaluating operating profit: |  |  |  |  |  |  |  |  |
| Business restructuring and severance costs |  | - |  | - |  | 9,700 |  | - |
| Adjusted operating profit | \$ | 3,380 | \$ | 3,620 | \$ | 10,570 | \$ | 13,730 |
|  |  |  |  |  |  |  |  |  |
| Corporate Expenses |  |  |  |  |  |  |  |  |
| Operating loss | \$ | $(6,220)$ | \$ | $(7,600)$ | \$ | $(45,220)$ | \$ | $(24,590)$ |
| Special Items to consider in evaluating operating loss: |  |  |  |  |  |  |  |  |
| Change in accounting policy for asbestos-related costs |  | - |  | - |  | 23,400 |  | - |
| M\&A diligence and transaction costs |  | 710 |  | 700 |  | 1,780 |  | 2,520 |
| Business restructuring and severance costs |  | - |  | - |  | 640 |  | - |
| Adjusted operating loss | \$ | $(5,510)$ | \$ | $(6,900)$ | \$ | $(19,400)$ | \$ | $(22,070)$ |
|  |  |  |  |  |  |  |  |  |
| Total Company |  |  |  |  |  |  |  |  |
| Net sales | \$ | 199,460 | \$ | 188,410 | \$ | 581,800 | \$ | 552,610 |
| Operating profit (loss) | \$ | $(108,320)$ | \$ | 23,570 | \$ | $(106,640)$ | \$ | 70,430 |
| Total Special Items to consider in evaluating operating profit |  | 137,910 |  | 1,060 |  | 185,740 |  | 4,600 |
| Adjusted operating profit | \$ | 29,590 | \$ | 24,630 | \$ | 79,100 | \$ | 75,030 |

## Additional Information on Non-GAAP Measures


${ }^{(1)}$ Income tax effect of Special Items is calculated on an item-by-item basis, utilizing the tax rate in the jurisdiction where the Special Item occurred. For the three and nine month periods ended September 30, 2020 and 2019, the income tax effect of Special Items varied from the tax rate inherent in the Company's reported GAAP results, primarily as a result of certain discrete items that occurred during the period for GAAP reporting purposes.
${ }^{(2)} 214,322$ and 222,906 shares for the three and nine months ended September 30,2020 , respectively, would have been dilutive to the computation of earnings per share in an income position.

|  | Three months ended September 30, |  |  |  | Nine months ended September 30, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  | 2019 |  | 2020 |  | 2019 |  |
| Adjusted operating profit | \$ | 29,590 | \$ | 24,630 | \$ | 79,100 | \$ | 75,030 |
| Corporate operating expenses (adjusted) |  | 4,420 |  | 5,120 |  | 13,650 |  | 15,080 |
| Non-cash stock compensation |  | 930 |  | 1,010 |  | 5,610 |  | 3,940 |
| Legacy expenses (adjusted) |  | 160 |  | 770 |  | 140 |  | 3,050 |
| Corporate expenses |  | 5,510 |  | 6,900 |  | 19,400 |  | 22,070 |
| Adjusted segment operating profit | \$ | 35,100 | \$ | 31,530 | \$ | 98,500 | \$ | 97,100 |
| Adjusted segment operating profit margin |  | 17.6\% |  | 16.7\% |  | 16.9\% |  | 17.6\% |


|  | Three months ended September 30, |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  |  |  |  | 2019 |  |  |  |  |  |
|  | As reported |  | Special Items | As adjusted |  | As reported |  | Special Items |  | As adjusted |  |
| Net cash provided by operating activities from continuing operations | \$ | 48,270 | 1,740 | \$ | 50,010 | \$ | 27,840 | \$ | 1,920 | \$ | 29,760 |
| Less: Capital expenditures |  | $(8,420)$ | - |  | $(8,420)$ |  | $(10,500)$ |  | - |  | $(10,500)$ |
| Free Cash Flow |  | 39,850 | 1,740 |  | 41,590 |  | 17,340 |  | 1,920 |  | 19,260 |
| Income (loss) from continuing operations |  | $(100,870)$ | 119,510 |  | 18,640 |  | 15,240 |  | 860 |  | 16,100 |
| Free Cash Flow as a percentage of income from continuing operations |  | NM |  |  | 223\% |  | 114\% |  |  |  | 120\% |


| Net cash provided by operating activities from continuing operations | Nine months ended September 30, |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  |  |  |  |  | 2019 |  |  |  |  |  |
|  | As reported |  | Special Items |  | As adjusted |  | As reported |  | Special Items |  | As adjusted |  |
|  | \$ | 79,110 | \$ | 7,100 | \$ | 86,210 | \$ | 60,610 | \$ | 4,130 | \$ | 64,740 |
| Less: Capital expenditures |  | $(17,670)$ |  | - |  | $(17,670)$ |  | $(22,000)$ |  | - |  | $(22,000)$ |
| Free Cash Flow |  | 61,440 |  | 7,100 |  | 68,540 |  | 38,610 |  | 4,130 |  | 42,740 |
| Income (loss) from continuing operations |  | $(103,450)$ |  | 155,850 |  | 52,400 |  | 48,510 |  | 3,740 |  | 52,250 |
| Free Cash Flow as a percentage of income from continuing operations |  | NM |  |  |  | 131\% |  | 80\% |  |  |  | 82\% |


|  | September 30, 2020 |  | $\begin{gathered} \text { December 31, } \\ 2019 \end{gathered}$ |  | September 30, 2019 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Current maturities, long-term debt | \$ | - | \$ | - | \$ | 30 |
| Long-term debt, net |  | 295,550 |  | 294,690 |  | 294,410 |
| Total Debt |  | 295,550 |  | 294,690 |  | 294,440 |
| Less: Cash and cash equivalents |  | 99,740 |  | 172,470 |  | 57,940 |
| Net Debt | \$ | 195,810 | \$ | 122,220 | \$ | 236,500 |


|  | Three months ended September 30, |  |  |  | Twelve months ended September 30, |  |  |  | Nine months ended September 30, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  |
| Income (loss) from continuing operations, as reported | \$ | $(100,870)$ | \$ | 15,240 | \$ | $(90,020)$ | \$ | 63,450 | \$ | $(103,450)$ | \$ | 48,510 |
| Depreciation expense |  | 6,930 |  | 6,340 |  | 28,240 |  | 23,710 |  | 21,700 |  | 18,330 |
| Amortization expense |  | 5,310 |  | 4,660 |  | 20,060 |  | 18,580 |  | 15,460 |  | 14,030 |
| Interest expense |  | 3,450 |  | 3,520 |  | 14,760 |  | 13,700 |  | 11,260 |  | 10,450 |
| Income tax expense |  | $(12,100)$ |  | 5,410 |  | $(11,000)$ |  | 17,560 |  | $(14,600)$ |  | 12,720 |
| Non-cash compensation expense |  | 930 |  | 1,090 |  | 7,930 |  | 6,900 |  | 5,610 |  | 4,130 |
| Adjusted EBITDA, before Special Items | \$ | $(96,350)$ | \$ | 36,260 | \$ | $(30,030)$ | \$ | 143,900 | \$ | $(64,020)$ | \$ | 108,170 |
| Adjusted EBITDA impact of Special Items |  | 137,900 |  | 980 |  | 184,080 |  | 4,650 |  | 184,160 |  | 4,410 |
| Adjusted EBITDA ${ }^{(1)}$ | \$ | 41,550 | \$ | 37,240 | \$ | 154,050 | \$ | 148,550 | \$ | 120,140 | \$ | 112,580 |
| Adjusted EBITDA as a percentage of net sales |  | 20.8\% |  | 19.8\% |  | 20.5\% |  | 20.6\% |  | 20.6\% |  | 20.4\% |
| Packaging | \$ | 34,230 | \$ | 26,820 | \$ | 118,590 | \$ | 106,350 | \$ | 93,360 | \$ | 80,780 |
| Aerospace |  | 8,160 |  | 11,470 |  | 38,560 |  | 43,520 |  | 27,140 |  | 32,910 |
| Specialty Products |  | 4,270 |  | 4,480 |  | 16,780 |  | 22,250 |  | 13,400 |  | 16,290 |
| Segment Adjusted EBITDA ${ }^{(1)}$ | \$ | 46,660 | \$ | 42,770 | \$ | 173,930 | \$ | 172,120 | \$ | 133,900 | \$ | 129,980 |
| Segment Adjusted EBITDA as a percentage of net sales |  | 23.4\% |  | 22.7\% |  | 23.1\% |  | 23.8\% |  | 23.0\% |  | 23.5\% |
| Other Corporate expenses |  | $(5,110)$ |  | $(5,530)$ |  | $(19,880)$ |  | $(23,570)$ |  | $(13,760)$ |  | $(17,400)$ |
| Adjusted EBITDA ${ }^{(1)}$ | \$ | 41,550 | \$ | 37,240 | \$ | 154,050 | \$ | 148,550 | \$ | 120,140 | \$ | 112,580 |

[^4]${ }^{(1)}$ Adjusted EBITDA is defined as income (loss) from continuing operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-
cash stock compensation, all as adjusted for the impact of Special Items. Segment Adjusted EBITDA excludes corporate expenses.


[^0]:    Note: All items are from continuing operations and adjusted for Special Items. Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions, except per share amounts.
    ${ }^{(1)}$ Adjusted EBITDA is defined as income (loss) from continuing operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock compensation, all as adjusted for the impact of Special Items. Segment Adjusted EBITDA excludes corporate expenses.

[^1]:    Note: All items are from continuing operations and adjusted for Special Items. Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions, except per share amounts.
    ${ }^{(1)}$ Adjusted EBITDA is defined as income (loss) from continuing operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock

[^2]:    Note: Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions. Amounts are from continuing operations.

[^3]:    Note: All items are adjusted for Special Items. Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions.
    ${ }^{(1)}$ Adjusted EBITDA is defined as income (loss) from continuing operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock compensation, all as adjusted for the impact of Special Items.

[^4]:    Unaudited, dollars in thousands.

